FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...

FibroGen (FGEN) announced that the China State Administration for Market Regulation approved the sale of FibroGen International to AstraZeneca ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now ...

Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...

FibroGen emphasized that the increased expected proceeds from the China sale and the extended cash runway support advancement of its lead programs, with FG-3246 and FG-3180 Phase II trials set to ...

(FGEN) on Monday reported a loss of $7.6 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a ...

View FibroGen, Inc. FGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

About FibroGen FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China, is a leading biopharmaceutical company ...

FibroGen intends to file the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden in the fourth quarter of 2025.

Conference Call and Webcast Presentation The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — FibroGen Inc. (FGEN) on Monday reported a loss of $7.6 million in its second quarter.